anti-CD97 synthetic antibody

The anti-CD97 synthetic antibody is a human monoclonal antibody developed by researchers at New York University (NYU) that targets CD97 (also known as Adhesion G protein-coupled receptor E5 or ADGRE5). CD97 is a member of the adhesion G protein-coupled receptor family and is significantly overexpressed in several aggressive cancers, including glioblastoma (GBM) and acute myeloid leukemia (AML), while remaining nearly undetectable in normal brain tissue. This synthetic antibody was engineered with human variable domain sequences and demonstrates nanomolar affinity and high selectivity for CD97 over its close homolog EMR2. It serves as a therapeutic agent by inhibiting tumor cell proliferation and inducing differentiation markers. Furthermore, it has been developed as the targeting moiety for antibody-drug conjugates (ADCs) using payloads such as monomethyl auristatin F (MMAF) or pyrrolobenzodiazepine (PBD) dimers, which have shown potent and selective cytotoxicity against GBM stem cells and AML cell lines in preclinical models.

Other names

anti-ADGRE5 synthetic antibodyanti-ADGRE-5 synthetic antibodyanti-ADGRE 5 synthetic antibody